Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.61 |
| ▸ | MERTK | Q12866 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 7/20 | 0.49 |
| ▸ | MAOA | P21397 | 4/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663248 | 0.88 | MAPT (0.59) | MERTKMAPTMAOBMAOACYP19A1 | |
| SCHEMBL810911 | 0.86 | VCAM1 (0.57) | VCAM1MERTKMAPTMAOBMAOA | |
| SCHEMBL2964633 | 0.85 | MAOB (0.52) | MAPTMAOBMAOASMN1; SMN2 | |
| SCHEMBL811395 | 0.83 | MAOB (0.50) | MAPTMAOBMAOARAB9ASMN1; SMN2 | |
| SCHEMBL810695 | 0.83 | MAPT (0.58) | MAPTMAOBCYP19A1RAB9ASMN1; SMN2 | |
| SCHEMBL810233 | 0.83 | SIRT2 (0.50) | MAPTMAOBMAOASMN1; SMN2 | |
| SCHEMBL810159 | 0.83 | MAOB (0.50) | MAPTMAOBMAOARAB9ASMN1; SMN2 | |
| SCHEMBL810842 | 0.82 | MEN1 (0.53) | VCAM1MAPTMAOBMAOARAB9A | |
| SCHEMBL29463873 | 0.82 | MEN1 (0.53) | VCAM1MAPTMAOBMAOARAB9A | |
| SCHEMBL7325804 | 0.80 | MAPT (0.53) | MERTKMAPTMAOBMAOACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| CN-101443334-A | Anti-viral compounds | ABBOTT LAB (US) | 2009-05-27 | — | — | CN | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | VCAM1 1503/4885MERTK 2634/4885MAPT 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.